Gain Therapeutics (GANX) Retained Earnings (2020 - 2026)

Gain Therapeutics has reported Retained Earnings for 7 years, with the latest figure at $121.9 million in Q2 2026.

• On a quarterly basis, Retained Earnings rose 28.83% year-over-year to $121.9 million in Q2 2026; TTM through Jun 2026 was $121.9 million, a 28.83% increase from a year earlier, with the FY2025 full-year figure at $119.1 million, up 34.2% from the prior year.
• Retained Earnings was $121.9 million for Q2 2026 at Gain Therapeutics, up from $120.0 million in the prior quarter.
• The five-year high for Retained Earnings was $121.9 million in Q2 2026, with the low at $56.1 million in Q1 2022.
• Average Retained Earnings over 5 years is $81.5 million, with a median of $79.1 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2024: Retained Earnings rose 2.6% in 2022, then soared 36.01% in 2024.
• Over 5 years, Retained Earnings stood at $57.4 million in 2022, then increased by 27.47% to $73.1 million in 2023, then increased by 21.43% to $88.8 million in 2024, then jumped by 34.2% to $119.1 million in 2025, then gained by 2.34% to $121.9 million in 2026.
• The last three Retained Earnings figures came in at $121.9 million (Q2 2026), $120.0 million (Q1 2026), and $119.1 million (Q4 2025), per Business Quant data.